CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 62.11 CNY -8.12% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CanSino Biologics Inc
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Short-Term Debt
ÂĄ883.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Short-Term Debt
ÂĄ1.1B
CAGR 3-Years
15%
CAGR 5-Years
6%
CAGR 10-Years
57%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Short-Term Debt
ÂĄ249m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
37%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Short-Term Debt
ÂĄ4.1B
CAGR 3-Years
20%
CAGR 5-Years
20%
CAGR 10-Years
21%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Short-Term Debt
ÂĄ318.9m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
67.83 CNY
Undervaluation 8%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Short-Term Debt?
Short-Term Debt
883.2m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Short-Term Debt amounts to 883.2m CNY.

What is CanSino Biologics Inc's Short-Term Debt growth rate?
Short-Term Debt CAGR 1Y
-43%

Over the last year, the Short-Term Debt growth was -43%.

Back to Top